Cardiol Therapeutics (CRDL) to Release Earnings on Thursday

Cardiol Therapeutics (NASDAQ:CRDL) is projected to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Cardiol Therapeutics to post earnings of ($0.09) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its earnings results on Thursday, August 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. On average, analysts expect Cardiol Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cardiol Therapeutics Trading Up 2.9%

Shares of NASDAQ CRDL opened at $1.05 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.46 and a current ratio of 2.46. The business’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.20. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.07. The company has a market cap of $103.84 million, a price-to-earnings ratio of -3.09 and a beta of 1.02.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CRDL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, October 8th. Brookline Capital Management upgraded shares of Cardiol Therapeutics to a “strong-buy” rating in a report on Wednesday, September 17th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cardiol Therapeutics has an average rating of “Buy” and a consensus target price of $8.00.

Institutional Trading of Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Bank of America Corp DE boosted its stake in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 136.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,455 shares of the company’s stock after buying an additional 15,255 shares during the period. Bank of America Corp DE’s holdings in Cardiol Therapeutics were worth $36,000 as of its most recent filing with the Securities & Exchange Commission. 12.49% of the stock is owned by institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.